Clinical identification of malignant pleural effusions

INTRODUCTION: Pleural effusions frequently signal disseminated cancer. Diagnostic markers of pleural malignancy at presentation that would assess cancer risk and would streamline diagnostic decisions remain unidentified. METHODS: A consecutive cohort of 323 patients with pleural effusion (PE) from different etiologies were recruited between 2013 and 2017 and was retrospectively analyzed. Data included history, chest X-ray, and blood/pleural fluid cell counts and biochemistry. Group comparison, receiver-operator characteristics, unsupervised hierarchical clustering, binary logistic regression, and random forests were used to develop the malignant pleural effusion detection (MAPED) score. MAPED was validated in an independent retrospective UK cohort (n = 238). RESULTS: Five variables showed significant diagnostic power and were incorporated into the 5-point MAPED score. Age > 55 years, effusion size > 50% of the most affected lung field, pleural neutrophil count

• Jia, J.
• Marazioti, A.
• Voulgaridis, A.
• Psallidas, I.
• Lamort, A. S.
• Iliopoulou, M.
• Krontira, A. C.
• Lilis, I.
• Asciak, R.
• Kanellakis, N. I.
• Rahman, N. M.
• Karkoulias, K.
• Spiropoulos, K.
• Liu, R.
• Kaiser, J. C.
• Stathopoulos, G. T.